查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018112

動物用藥品市場：2026-2032年全球市場預測（依產品類型、給藥途徑、目標動物、適應症、通路及最終用戶分類）

Veterinary Pharmaceuticals Market by Product Type, Route of Administration, Animal Type, Indications, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年動物用藥品市值為447.8億美元，預計到2026年將成長至485.7億美元，複合年成長率為8.70%，到2032年將達到803.1億美元。

主要市場統計數據
基準年 2025 447.8億美元
預計年份：2026年 485.7億美元
預測年份 2032 803.1億美元
複合年成長率 (%) 8.70%

透過全面捕捉和整合臨床創新、監管壓力和相關人員的優先事項，我們重新定義了獸藥面臨的策略挑戰。

動物用藥品產業正處於關鍵的轉折點，隨著科學進步、動物照護模式的轉變以及監管的加強，產品研發、分銷和推廣方式正在發生根本性的變革。本導言概述了影響相關人員（包括製造商、獸醫、動物健康網路和終端使用者）優先事項的關鍵因素。此外，本導言還著重分析了治療方法創新、合理使用抗生素以及影響整個價值鏈決策的商業性動態之間的相互作用，從而提供了更廣泛的視角。

生物技術、數位診斷和合理使用政策帶來的策略性環境變化正在重塑發展、分銷和投資重點。

從實驗室到農場和診所，一系列協同變化正在重塑產業格局。生物技術驅動的疫苗和新型抗菌藥物正在重塑治療路徑，而數位健康工具和遠端醫療對伴侶動物和牲畜的處方行為和用藥依從性正產生日益顯著的影響。這些技術進步縮短了診斷時間，實現了更精準的干涉，改變了對傳統頻譜藥物的需求模式，並將投資轉向靶向性強、循證的產品。

2025 年關稅調整將如何重塑整個獸藥價值鏈的籌資策略、供應鏈在地化和商業環境？

2025年實施的關稅調整的累積影響正在擴大整個動物醫藥系統在成本、供應鏈和策略採購方面的考量。製造商和經銷商正在重新思考其籌資策略，以在確保能夠從全球供應商獲得關鍵活性藥物成分、輔料和特殊包裝的同時，降低關稅相關的成本上漲。這種重新思考凸顯了供應商多元化、關鍵生產流程近岸外包以及重新談判商業條款的重要性，以在不影響品質或合規性的前提下維持獲利能力。

透過對產品、目標動物物種、給藥途徑、適應症、分銷管道和最終用戶進行綜合細分分析，可以製定有針對性的開發和商業化策略。

有效的市場區隔揭示了價值創造與臨床需求的交集，有助於產品策略和銷售管道的開發。從產品角度來看，市場涵蓋藥品、飼料藥品和疫苗。藥品細分包括鎮痛藥、感染疾病、抗發炎藥和驅蟲藥。感染疾病又細分為抗生素和抗真菌藥物，而抗發炎藥則分為非類固醇類和類固醇類。驅蟲藥進一步分為體外驅蟲藥和體內驅蟲藥。藥用飼料包括抗生素飼料、驅蟲飼料、生長促進劑、營養飼料和益生菌/益生元飼料。疫苗細分基於平台和風險等級，將疫苗分為去活化疫苗和活病毒疫苗，每種疫苗對低溫運輸和監管的要求各不相同。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和細微的監管差異正在影響著進入、部署和供應鏈策略。

區域趨勢因地域條件不同，對法律規範、供應鏈韌性和商業性機會的影響也各不相同。在美洲，先進的伴侶動物療法的高滲透率、不斷進步的獸醫標準以及強大的零售和獸醫分銷網路加速了新配方的推廣應用，從而推動了市場活躍度。由於區域內的交易行為和報銷機制存在差異，製造商需要調整定價策略，並強調產品安全性和便利性，以滿足寵物飼主和大型農場的需求。

透過整合研發、卓越的生產能力和策略夥伴關係，實現競爭差異化，加速生技藥品和先進療法的商業化。

該領域的競爭格局由大型跨國公司、專業生物技術公司和高度靈活的契約製造(CMO) 組成。主要企業憑藉其整合研發能力、先進製造技術和廣泛商業網路的能力脫穎而出，從而實現生物製藥和複雜製劑的快速規模化生產。策略聯盟和授權協議十分普遍，尤其是在疫苗平台開發和新型抗寄生蟲藥物的化學設計方面，各企業力求利用專業技術供應商的技術來補充自身的技術優勢。

採取切實可行的策略措施，協調研發重點、供應鏈韌性、管理以及數位化驅動的商業化，以建立永續的競爭優勢。

產業領導企業必須將自身策略與兩大基本要素──創新和供應鏈韌性──相契合，才能獲得臨床和商業性價值。優先發展標靶治療和預防性生物製藥的研發項目，並將合理的抗菌藥物使用納入產品標籤、行銷和上市後監測活動，以滿足監管和社會期望，至關重要。投資於能夠提高患者依從性、減少給藥頻率和簡化給藥方式的製劑技術，將有助於臨床醫生和患者更好地接受這些療法。

採用穩健的混合調查方法，結合與關鍵相關人員的訪談、科學文獻綜述、監管分析和供應鏈映射，以獲得可操作的見解。

本分析採用多方面調查方法，以確保研究結果的穩健性，並將關鍵相關人員的見解與二手科學和監管文獻進行交叉比對。主要研究活動包括對獸醫、行業高管、生產合作夥伴和分銷管道負責人進行結構化檢驗，以了解營運現狀、未滿足的需求和採購趨勢。這些定性資訊與公開的監管文件、同行評審的科學論文和企業資訊披露相結合，用於檢驗治療趨勢並評估政策變化帶來的實際影響。

一項旨在將科學進步轉化為永續商業性成果的決定性整合，強調創新協調、管理整合和供應鏈重組。

總之，在生技藥品和標靶治療的創新、監管預期變化以及貿易調整和流通結構轉變帶來的商業性壓力等因素的共同推動下，動物用藥品產業正經歷著一場意義深遠的變革。這些因素共同要求企業在產品設計、證據產生和供應鏈建構方面採取更具策略性的方法。那些積極實踐管理原則、投資開發有助於提升合規性的產品並建立能夠抵禦關稅波動影響的採購體系的企業，將更有能力在滿足臨床醫生和飼主期望的同時，維持利潤率。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物用藥品市場：依產品類型分類

  • 製藥
    • 止痛藥
    • 抗感染藥物
      • 抗生素
      • 抗真菌藥物
      • 抗病毒藥物
    • 抗發炎藥
      • NSAIDs
      • 皮質類固醇
    • 殺蟲劑
    • 麻醉劑
    • 鎮靜劑
  • 藥用飼料添加劑
  • 疫苗
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 重組疫苗

第9章：動物用藥品市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 皮下
  • 口服
    • 咀嚼片
    • 懸浮液/糖漿
    • 藥片
  • 外用
    • 噴
    • 粉末
    • 軟膏

第10章：動物用藥品市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
    • 馬
  • 家畜
    • 牛
    • 家禽
    • 綿羊/山羊
    • 豬

第11章：動物用藥品市場依適應症分類

  • 慢性疼痛和急性疼痛管理
  • 免疫系統疾病
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 整形外科疾病
  • 寄生蟲感染疾病
  • 生殖健康

第12章：動物用藥品市場：依通路分類

  • 線上
  • 離線

第13章：動物用藥品市場：依最終用戶分類

  • 畜牧場
  • 寵物飼主
  • 獸醫醫院和診所

第14章動物用藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：動物用藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章動物用藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國動物用藥品市場

第18章：中國動物用藥品市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurora Pharmaceutical, Inc.
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • China Animal Husbandry Industry Co., Ltd.
  • Dechra Pharmaceuticals PLC
  • ECO Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation by Mars, Incorporated
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Laboratorio Drag Pharma Chile Invetec SA
  • Merck & Co., Inc.
  • Neogen Corporation
  • Norbrook Group
  • Phibro Animal Health Corporation
  • Teknofarma Srl
  • Vetoquinol Group
  • Vetpharma Animal Health SL by Insud Pharma SLU
  • Virbac SA
  • Zendal Group
  • Zoetis Inc.
Product Code: MRR-032F197B035E

The Veterinary Pharmaceuticals Market was valued at USD 44.78 billion in 2025 and is projected to grow to USD 48.57 billion in 2026, with a CAGR of 8.70%, reaching USD 80.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.78 billion
Estimated Year [2026] USD 48.57 billion
Forecast Year [2032] USD 80.31 billion
CAGR (%) 8.70%

Comprehensive framing of clinical innovation, regulatory pressures, and stakeholder priorities that together redefine strategic imperatives in veterinary pharmaceuticals

The veterinary pharmaceuticals sector stands at a pivotal juncture where scientific progress, evolving animal care paradigms, and heightened regulatory scrutiny converge to redefine how products are developed, distributed, and deployed. This introduction synthesizes the critical forces that are shaping stakeholder priorities across manufacturers, veterinarians, animal health networks, and end users. It frames the broader context by emphasizing the interplay between therapeutic innovation, antimicrobial stewardship, and commercial dynamics that influence decision-making across the value chain.

Emerging therapeutic modalities, such as precision antiparasitics, refined vaccine platforms, and formulations tailored to compliance in companion animals, are challenging legacy product portfolios and operational models. Concurrently, payers and procurement channels are demanding clearer evidence of clinical value and safety, while regulatory authorities are tightening oversight on residues and risk mitigation. These pressures are creating both constraints and opportunities: companies focused on targeted indication development, improved delivery systems, and integrated services are best positioned to meet shifting clinical expectations. Throughout this introduction, the emphasis remains on understanding how technological advances and policy shifts interact to create near-term strategic imperatives for industry participants.

Strategic landscape shifts driven by biotechnology, digital diagnostics, and stewardship policies that are reconfiguring development, distribution, and investment priorities

The landscape is being transformed by a suite of converging shifts that extend from the laboratory to the farm and the clinic. Biotechnology-enabled vaccines and novel antimicrobial alternatives are reshaping therapeutic pathways, while digital health tools and telemedicine increasingly influence prescribing behavior and adherence across companion and livestock populations. These technological advances reduce time to diagnosis and enable more precise interventions, thereby altering demand patterns for traditional broad-spectrum drugs and shifting investment toward targeted, evidence-backed products.

At the same time, regulatory and societal emphasis on antimicrobial stewardship is accelerating the adoption of medicated-feed alternatives, biologics, and preventive strategies, prompting manufacturers to reformulate pipelines and revisit lifecycle strategies. Market participants are also contending with evolving procurement channels as online pharmacies and integrated veterinary services gain traction, driving new distribution and commercialization models. Financial sponsors and strategic partners are prioritizing companies that demonstrate robust data packages, scalable manufacturing, and agility in supply chain management. In sum, the most consequential shifts are technological maturation, regulatory tightening, channel evolution, and investor preference for data-driven, scalable asset portfolios.

How 2025 tariff adjustments are reshaping sourcing strategies, supply chain localization, and commercial terms across the veterinary pharmaceuticals value chain

The cumulative impact of tariff adjustments introduced in 2025 has amplified cost, supply chain, and strategic sourcing considerations across the veterinary pharmaceuticals ecosystem. Manufacturers and distributors are recalibrating procurement strategies to mitigate tariff-related cost inflation while preserving access to critical active pharmaceutical ingredients, excipients, and specialized packaging sourced from global suppliers. This recalibration is prompting a renewed emphasis on supplier diversification, nearshoring of critical manufacturing steps, and renegotiation of commercial terms to maintain margin stability without compromising quality or regulatory compliance.

These fiscal headwinds also affect downstream stakeholders, including veterinary clinics and animal farms, which face pressure to optimize inventory and prioritize high-value interventions. In response, companies are accelerating investments in local manufacturing partnerships and contract development and manufacturing organizations that can offer tariff-resilient supply chains. Simultaneously, longer-term strategic responses include redesigning product portfolios to reduce reliance on tariff-exposed inputs and increasing collaboration with regional partners to streamline customs processes and compliance documentation. Collectively, these measures reduce exposure to future trade shocks and support continuity of therapeutic availability for both companion animals and livestock populations.

Integrated segmentation analysis across products, species, administration modes, indications, channels, and end users to inform targeted development and commercialization strategies

Effective segmentation reveals where value creation and clinical need intersect, informing product strategy and channel deployment. When examined by product, the market encompasses Drugs, Medicinal Feed, and Vaccines. Within Drugs, subcategories include Analgesics, Anti-Infectives, Anti-Inflammatories, and Parasiticides, and the anti-infective category further differentiates into Antibiotics and Antifungals while anti-inflammatory therapies separate into Non-Steroidal and Steroidal approaches; parasiticide treatments divide into Ectoparasiticides and Endoparasiticides. Medicinal Feed covers antibiotic medicated feed, antiparasitic medicated feed, growth promoters, nutritional medicated feed, and probiotic and prebiotic medicated feed. Vaccine segmentation is driven by platform and risk profile, distinguishing between inactivated vaccines and live vaccines, each with distinct cold-chain and regulatory implications.

Segmenting by animal type clarifies demand drivers and regulatory pathways, with Companion Animals split into Cats, Dogs, and Horses and Livestock Animals encompassing Cattle, Poultry, Sheep and Goats, and Swine, each species presenting unique therapeutic needs and administration practices. Mode of administration further influences formulation strategy, where Injectable routes include intramuscular and subcutaneous delivery, Oral forms cover capsules, liquid suspensions and syrups, and tablets, and Topical products are formulated as creams, lotions, and ointments; administration mode affects adherence, required caregiver skill, and product stability. Indication-based segmentation highlights focus areas such as chronic and acute pain management, immunological conditions, infectious diseases, metabolic and neurological disorders, orthopedic conditions, parasitic infections, and reproductive health, guiding clinical evidence generation and label claims. Distribution channels span online pharmacies, retail pharmacies, and veterinary clinics, each with different purchasing behaviors and regulatory obligations, while end users consist of animal farms, pet owners, and veterinary hospitals, informing pricing, packaging, and support services. Integrating these segmentation layers enables more precise targeting of R&D investments, commercialization plans, and post-market surveillance strategies.

Regional dynamics and regulatory nuances across the Americas, Europe Middle East Africa, and Asia-Pacific that determine access, adoption, and supply chain strategies

Regional dynamics shape regulatory frameworks, supply chain resilience, and commercial opportunity in distinct ways across geographies. In the Americas, market activity is driven by high adoption rates of advanced therapeutics in companion animals, progressive veterinary practice standards, and a robust network of retail and clinic-based distribution that accelerates uptake of novel formulations. Transactional behaviors and reimbursement nuances vary within the region, prompting manufacturers to adapt pricing strategies and to emphasize product safety and convenience for pet owners and large-scale farms alike.

Europe, the Middle East & Africa combine rigorous regulatory environments with diverse market maturities. Established European markets emphasize antimicrobial stewardship, stringent residue controls, and strong public sector engagement in livestock health, while markets in the Middle East and Africa present both growth opportunities and logistical complexities, including variability in cold-chain infrastructure and differing import regulations. Asia-Pacific is characterized by rapid modernization of livestock operations, intensifying demand for preventive vaccines and medicated feed solutions, and a growing companion animal segment with rising willingness to invest in advanced therapeutics. Supply chain considerations and local manufacturing partnerships play a pivotal role in all regions, and regulatory harmonization efforts, where they exist, materially influence market entry strategies and product lifecycle management.

Competitive differentiation through integrated R&D, manufacturing excellence, and strategic partnerships that accelerate biologics and advanced therapeutic commercialization

Competitive positioning in the sector reflects a mix of large multinational players, specialized biotechnology firms, and agile contract manufacturers. Leading companies differentiate through integrated capabilities that combine R&D strength, advanced manufacturing, and broad commercial networks, enabling rapid scale-up of biologics and complex formulations. Strategic alliances and licensing agreements are common as organizations seek to complement in-house expertise with niche technology providers, particularly in vaccine platform development and novel antiparasitic chemistries.

Innovation is increasingly financed through targeted partnerships, where larger firms provide capital and commercialization pathways while smaller entities supply scientific novelty. Companies that invest in digital tools for adherence monitoring, telehealth-enabled prescribing, and data-driven pharmacovigilance strengthen relationships with veterinarians and animal owners. Operational excellence in cold-chain logistics, regulatory affairs, and manufacturing quality is a persistent differentiator, as is the ability to demonstrate robust clinical evidence and stewardship frameworks. Overall, the competitive landscape rewards firms that combine scientific innovation with disciplined commercialization and supply chain resilience.

Practical strategic actions to align R&D focus, supply chain resilience, stewardship, and digital-enabled commercialization for sustainable competitive advantage

Industry leaders should align strategy with the twin imperatives of innovation and supply chain resilience to capture clinical and commercial value. Prioritize development programs that emphasize targeted therapeutics and preventative biologics, while embedding antimicrobial stewardship into labeling, marketing, and post-market surveillance activities to satisfy regulatory and societal expectations. Investing in formulation technologies that improve patient adherence, reduce dosing frequency, and simplify administration will drive uptake among clinicians and owners alike.

Simultaneously, reconfigure sourcing strategies to reduce tariff exposure and build redundancy through diversified supplier networks and regional manufacturing partnerships. Strengthen commercialization by integrating digital engagement platforms with traditional distribution channels to support telemedicine workflows, adherence monitoring, and data collection that bolster real-world evidence generation. Pursue collaborations and licensing models to accelerate access to novel platforms, while deploying rigorous pharmacovigilance and quality systems to maintain trust across stakeholders. Finally, tailor market entry plans to regional regulatory environments and species-specific needs to ensure alignment between clinical value propositions and local practice patterns.

Robust mixed-methods methodology combining primary stakeholder interviews, scientific literature review, regulatory analysis, and supply chain mapping to ensure actionable insights

The research methodology underpinning this analysis combined a multifaceted approach to ensure robustness, triangulating primary stakeholder insights with secondary scientific and regulatory literature. Primary engagements included structured interviews with veterinarians, industry executives, manufacturing partners, and distribution channel leaders to capture operational realities, unmet clinical needs, and procurement dynamics. These qualitative inputs were synthesized with public regulatory documents, peer-reviewed scientific studies, and corporate disclosures to validate therapeutic trends and to assess the practical implications of policy shifts.

Analytical steps included segmentation mapping across product types, species, administration routes, indications, distribution channels, and end users, enabling granular interpretation of where clinical demand aligns with commercial opportunity. Supply chain analysis focused on sourcing exposures, tariff impacts, and manufacturing capacity constraints. Finally, competitive assessment prioritized capabilities in R&D, manufacturing, regulatory affairs, and digital engagement. Throughout the methodology, care was taken to ensure transparency of assumptions and to corroborate findings through multiple independent sources, enhancing confidence in the conclusions and recommendations presented.

Conclusive synthesis emphasizing innovation alignment, stewardship integration, and supply chain redesign to translate scientific advances into durable commercial outcomes

In conclusion, the veterinary pharmaceuticals sector is navigating a period of substantive change driven by innovation in biologics and targeted therapeutics, evolving regulatory expectations, and commercial pressures stemming from trade adjustments and shifting distribution dynamics. These factors collectively require companies to be more strategic in product design, evidence generation, and supply chain configuration. Firms that proactively integrate stewardship principles, invest in formulating products that enhance compliance, and establish tariff-resilient sourcing will be better positioned to meet clinician and owner expectations while preserving operational margins.

The path forward involves a balanced approach: accelerate development of vaccines and targeted antiparasitics that reduce reliance on broad-spectrum antimicrobials, modernize manufacturing and logistics to mitigate trade-related disruptions, and adopt digital tools that enhance clinical decision-making and adherence. By aligning innovation priorities with regional regulatory nuances and end-user behaviors, organizations can translate scientific advances into durable commercial outcomes and improved animal health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pharmaceuticals Market, by Product Type

  • 8.1. Drugs
    • 8.1.1. Analgesics
    • 8.1.2. Anti-Infectives
      • 8.1.2.1. Antibiotics
      • 8.1.2.2. Antifungals
      • 8.1.2.3. Antivirals
    • 8.1.3. Anti-Inflammatories
      • 8.1.3.1. NSAIDs
      • 8.1.3.2. Corticosteroids
    • 8.1.4. Parasiticides
    • 8.1.5. Anaesthetics
    • 8.1.6. Anesthetic
  • 8.2. Medicated Feed Additives
  • 8.3. Vaccines
    • 8.3.1. Inactivated Vaccines
    • 8.3.2. Live Attenuated Vaccines
    • 8.3.3. Recombinant Vaccines

9. Veterinary Pharmaceuticals Market, by Route of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Chews
    • 9.2.2. Liquid Suspension & Syrup
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Sprays
    • 9.3.2. Powders
    • 9.3.3. Ointments

10. Veterinary Pharmaceuticals Market, by Animal Type

  • 10.1. Companion Animals
    • 10.1.1. Cats
    • 10.1.2. Dogs
    • 10.1.3. Horses
  • 10.2. Livestock Animals
    • 10.2.1. Cattle
    • 10.2.2. Poultry
    • 10.2.3. Sheep & Goats
    • 10.2.4. Swine

11. Veterinary Pharmaceuticals Market, by Indications

  • 11.1. Chronic & Acute Pain Management
  • 11.2. Immunological Conditions
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Orthopedic Disorders
  • 11.7. Parasitic Infections
  • 11.8. Reproductive Health

12. Veterinary Pharmaceuticals Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Veterinary Pharmaceuticals Market, by End User

  • 13.1. Animal Farms
  • 13.2. Pet Owners
  • 13.3. Veterinary Hospitals & Clinics

14. Veterinary Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Veterinary Pharmaceuticals Market

18. China Veterinary Pharmaceuticals Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aurora Pharmaceutical, Inc.
  • 19.6. Biogenesis Bago S.A.
  • 19.7. Biovac Ltd.
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Ceva Sante Animale
  • 19.10. Chanelle Pharma
  • 19.11. China Animal Husbandry Industry Co., Ltd.
  • 19.12. Dechra Pharmaceuticals PLC
  • 19.13. ECO Animal Health Group PLC
  • 19.14. Elanco Animal Health Incorporated
  • 19.15. Heska Corporation by Mars, Incorporated
  • 19.16. Hester Biosciences Limited
  • 19.17. Indian Immunologicals Ltd.
  • 19.18. Intas Pharmaceuticals Ltd.
  • 19.19. Laboratorio Drag Pharma Chile Invetec S.A.
  • 19.20. Merck & Co., Inc.
  • 19.21. Neogen Corporation
  • 19.22. Norbrook Group
  • 19.23. Phibro Animal Health Corporation
  • 19.24. Teknofarma S.r.l.
  • 19.25. Vetoquinol Group
  • 19.26. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
  • 19.27. Virbac S.A.
  • 19.28. Zendal Group
  • 19.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANAESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANESTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHEWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORTHOPEDIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)